A new theory was developed, assuming that a cost-effectiveness function specific to a disease area is known as the form of C = f (E) (where C:cost and E:effectiveness), on the curve of which treatment alternatives are located as points, at least two points P 1 and P 0 having a pair of C and E on the C-E plane. The point P 1 represents the best comparator, and P 0 as the second best for a new technology X notified at the point P x (e x (known), C x (not determined)). Existence of such a cost-effectiveness function is a pre-requisite for our tangent methods [1, 2] . Under those assumptions, we estimated three benchmarks based on the cost-effectiveness function: 1) the ICER represented by the slope from P 0 to P 1 , 2) the tangent at P 1 , 3) the tangent at the point on the cost-effectiveness curve which intersects with the vertical line at the point: (E, C)=(e x , 0). Furthermore, the magnitude of relationship was examined between the three benchmarks and the ICER of the technology X defined by the slope of the line connecting P x with P 1 .
Multiple decision criteria at six levels were identified and formulated as for acceptance of a new health technology as shown in Figure 1 : 1) accepted (simple dominance), 2) preferred (extended dominance), 3) less preferred, 4) minimally preferred, 5) not preferred, but negotiable, and 6) not accepted. Those six levels are defined by identifying five benchmarking points: D1(ex, C1) to D5(ex, C5) that locate on the vertical line at ex. Those were identified as points of intersection with the lines/curve: 1) (for D2) the extension between P0 and P1, 2) (for D3) the tangent at P1, and 3) (for D5) the line through P1 which is parallel to the tangent at D4, and also 4) (for D4) the curve of the cost-effectiveness function.
The range of decision level was determined by theoretical development with the equations as follows:
, where the notation of f '(e) denotes the derivative of cost-effectiveness function f (E) at E = e.
Our study offers a new approach for making multi-decisions on a target technology in the context of its alternatives, which are specific to a disease category and already available in the market. It would be useful in making reimbursement and pricing decisions with scientific ground as a natural extension beyond the NICE assessment using single-threshold.
To develop a new method that naturally extends the UK NICE way of single-threshold for incremental cost-effectiveness ratio (ICER). It aims to provide multiple decision criteria for assessing an ICER of expensive health technologies such as molecular-targeted cancer drugs and regenerative medicine products.
ISPOR The cost Cx of a new technology can take 6 levels on the vertical line, E = ex:
1) less than C1, 2) between C1 and C2, 3) between C2 and C3, 4) between C3 and C4, 5) between C4 and C5, and 6) more than C5. Each level corresponds to a decision as shown in the figure from "unconditionally accepted" to "not accepted", respectively.
The Px in the figure illustrates an example when Cx locates between C1 and C2. The decision points D1 to D5 are defined as follows: D1: a point with ex and C1, D2: a point at which the line between P0 and P1 extends and intersects with the vertical line at ex, D3: a point at which the tangent at P1 intersects with the vertical line at ex, D4: a point at which the C-E curve intersects with the vertical line at ex, D5: a point at which the line through P1, parallel to the tangent at D4, intersects with the vertical line at ex. Estimated based on hypothetical two comparators: P0(6.09QALY, 50,000USD) and P1(7.68QALY, 100,000USD) on the cost-effectiveness curve with QALY= −2.83+2.28 ln(Cost) for HIV/AIDS tertiary prevention, assuming the benefit of a new intervention is 8.59QALY, which corresponds to 150,000USD on the cost-effectiveness curve .
To clarify the concept of our tangent methods for multiple ICERs decision, numerical calculations were performed based on the HIV/AIDS case [3, 4] . Let a hypothetical new tertiary intervention for HIV/AIDS have the clinical benefit with 8.59QALY, compared to the primary comparator P1(7.68QALY, 100,000USD) and the secondary one P0(6.09QALY, 50,000USD) on the cost-effectiveness curve with the function: QALY= −2.83+2.28 ln(Cost) and the derivative: f '(QALY)=2.28/Cost. The results are shown at Table 1 , which indicates the new technology cannot be accepted over 65,789USD/QALY, and suggests that a higher threshold could be allowed beyond 50,000USD/QALY commonly recognized as a standard.
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